Antihypertensive Patient Education

The complete history of patient education is RL. RL is an 81 year old white man who is allergic to Levaquin. He was admitted to the hospital because of a fall and stayed on the floor for 12 hours before being found. He acknowledges that the diagnosis may be a secondary diagnosis of sepsis and systemic inflammatory response syndrome (SIRS), community pneumonia. He has a history of chronic obstructive pulmonary disease (COPD), bilateral paw edema, and undefined essential hypertension.

I advise patients to keep taking antihypertensive medicine. Educate patients about the possible side effects of drugs, uncontrolled complications of hypertension, and the importance of following treatment. I also advised him to go to the nearest Klinik Kesihatan for regular follow-up. I also motivate him to stop him by explaining to him the harmful effects of smoking. Dear Doctor, this patient, Thank you for seeing Sulaiman, a 69 - year - old Malesian gentleman of high blood pressure in the past 10 years. He was hospitalized on February 28, 2011 due to secondary abdominal obstruction due to adhesions. In 1998, there was a history of laparotomy because of S - shaped intestinal torsion. He has a family history of colon cancer. After conservative management, he left the hospital on March 4, 2011.

As this patient has a history of chronic renal failure and hypertension, it is administered antihypertensive drug (ACE inhibitor), loop diuretic, vitamin and mineral supplement, especially vitamin D supplement. Because of the advanced development of antibiotic science, people are extremely concerned about the worsening of diseases. The kidneys are organs used to excrete drug metabolic waste (). He is bound by a protein diet. Alcoholism is associated with many medical problems that are detrimental to the normal functioning of the body.

When evaluating the patient's response to drugs against hypertension, biomarkers are as common as blood pressure monitoring, genetic mutations that determine the risk of breast cancer in patients, genetic mutations that cause certain types of leukemia, Targeted and excluded by powerful drugs to protect healthy cells with. Instead of waiting years to determine the survival rate, the FDA can quickly approve new anticancer drugs using alternative endpoints (such as tumor size reduction).